Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ERN1 | O75460 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924908 | 0.90 | ERN1 (0.48) | LMNAERN1 | |
| SCHEMBL14924882 | 0.88 | ERN1 (0.52) | LMNAERN1TP53 | |
| SCHEMBL14924896 | 0.88 | ERN1 (0.59) | LMNAERN1TP53ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL14917112 | 0.87 | ERN1 (0.51) | LMNAERN1TP53 | |
| Hydrochloric Acid SCHEMBL30406628 | 0.87 | ERN1 (0.51) | LMNAERN1TP53 | |
| SCHEMBL14924914 | 0.79 | ERN1 (0.59) | LMNAERN1ALDH1A1HPGD | |
| SCHEMBL22840651 | 0.78 | LMNA (0.53) | LMNATP53ALDH1A1HPGDMAPT | |
| SCHEMBL14924898 | 0.77 | ERN1 (0.63) | LMNAERN1TP53HPGDMAPT | |
| SCHEMBL14924892 | 0.77 | ERN1 (0.63) | ERN1 | |
| SCHEMBL14924906 | 0.77 | ERN1 (0.55) | LMNAERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-10357475-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-07-23 | — | — | US | disclosed |
| US-9867803-B2 | IRE-1α inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-9867803-B2 | IRE-1α inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-11-16 | — | — | US | disclosed |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-11-16 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141424-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | LMNA 2261/4885ERN1 1/4885CA12 4856/4885 |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | LMNA 2261/4885ERN1 1/4885CA12 4856/4885 |
| US-11337956-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | LMNA 2296/4885ERN1 2/4885CA12 4859/4885 |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | LMNA 2261/4885ERN1 1/4885CA12 4856/4885 |
| US-10357475-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | LMNA 2296/4885ERN1 2/4885CA12 4859/4885 |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | LMNA 1903/4885ERN1 1/4885CA12 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.